NCT06810375 Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery
| NCT ID | NCT06810375 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | George Washington University |
| Condition | Lung Cancers |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2028-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 120 participants in total. It began in 2025-03-01 with a primary completion date of 2028-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.
Eligibility Criteria
Inclusion Criteria: * Video assisted pulmonary resection, pleurodesis or decortication Exclusion Criteria: * Allergy to local anesthetics * Patient undergoing bilateral surgery * Surgery is emergent as deemed by the principal investigator
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06810375 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Lung Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06810375 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 120 participants.
Is NCT06810375 currently recruiting?
Yes, NCT06810375 is actively recruiting participants. Contact the research team at eshaykhinurov@mfa.gwu.edu for enrollment information.
Where is the NCT06810375 trial being conducted?
This trial is being conducted at Washington D.C., United States.
Who is sponsoring the NCT06810375 clinical trial?
NCT06810375 is sponsored by George Washington University. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.